LA-SER is a strongly science driven late-phase company with offices in 7 countries (UK, France, Germany, Spain, Italy, Canada and Morocco) encompassing a team of 150 specialists in late-phase clinical research.
We cover a full range of late-phase services from observational studies, cohorts, registries, case-control studies, surveys, electronic health care database studies, pragmatic trials; we excel in risk/benefit management, effectiveness/relative effectiveness studies, and strategic consulting for drug value assessment.
A truly unique feature is our in-depth understanding and knowledge of the process of drug value assessment, and of the methods, paradigms and modus operandi of regulatory decision-making bodies and agencies in several countries. Originally brought to the company by the founders of the company, this in-depth network knowledge is now shared by a large number of our senior staff. We can therefore provide remarkable insight into what evidence is required to grant market authorisation and reimbursement, for new drugs across different European countries and North America. Thanks to a network of key advisors from several countries, we also adapt very quickly to the changing environment.
